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It is well-documented that early HIV diagnosis and 
linkage to care reduces morbidity and mortality as well 
as HIV transmission. We estimated the median time 
from HIV infection to diagnosis in the European Union/
European Economic Area (EU/EEA) at 2.9 years in 2016, 
with regional variation. Despite evidence of a decline 
in the number of people living with undiagnosed HIV 
in the EU/EEA, many remain undiagnosed, including 
33% with more advanced HIV infection (CD4 < 350 cells/
mm3).
HIV remains an important public health issue affecting 
the 31 countries of the European Union and European 
Economic Area (EU/EEA) [1]. In 2015, it was estimated 
that ca 120,000 people (15% of those living with HIV 
in the EU/EEA) were living with undiagnosed HIV infec-
tion [2]. In order to understand regional variations in 
(i) HIV incidence, (ii) time to HIV diagnosis, and (iii) 
the number of people living with undiagnosed HIV, we 
analysed HIV and AIDS surveillance data from 2003 
through 2016.
Calculation of 2016 estimates
Annually, HIV surveillance data are reported by EU/EEA 
countries to a database for HIV/AIDS that is coordinated 
jointly by the European Centre for Disease Prevention 
and Control (ECDC) and the World Health Organization 
(WHO) Regional Office for Europe within the European 
Surveillance System (TESSy) [1].
Countries were grouped into four geographical regions 
(East, South, West, North) (Figure 1) based on a United 
Nations definition [3]. For those countries lacking data 
on CD4 count at diagnosis, the distribution of CD4 
count in the region they belonged to was assumed to 
be representative. When grouping countries, the epi-
demic characteristics across countries were pooled and 
a similar probability of diagnosis by CD4 cell count cat-
egory for all countries within that region was assumed.
 
Annual data on HIV diagnoses reported to TESSy for 
2003–2016 were adjusted for reporting delay and 
under-reporting. Data were adjusted for non-national 
coverage of some countries’ reporting systems (2003–
2011 for Italy and 2003–2012 for Spain) and cases (3%) 
that had been previously reported as diagnosed were 
excluded. Data were then stratified by the presence 
of a concurrent AIDS diagnosis and, for people with-
out concurrent AIDS, by CD4 cell count levels at the 
time of diagnosis i.e. ≥ 500, 350–499, 200–349, < 200 
cells/mm3 [4]. The ‘incidence method’ in the European 
Centre for Disease Prevention and Control (ECDC) HIV 
Modelling Tool version 1.3.0 was used for each region in 
2016 to estimate the (i) HIV incidence, (ii) median time 
from infection to diagnosis, and (iii) number of people 
living with HIV who were not yet diagnosed [5,6].
HIV incidence in 2016 
In 2016, 29,444 cases of HIV were diagnosed and 
reported in the EU/EEA, resulting in a notification rate 
of 5.9 per 100,000 population when adjusted for report-
ing delay [1]. Rates in 2010–2015 had ranged from 6.5 
to 6.7 and in 2016, for the first time in a decade, there 
was a clear decline in the rate of new HIV diagnoses at 
EU/EEA level although rates in 11 of 31 EU/EEA coun-
tries have continued to increase.
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In 2016, the estimated number of new HIV infections 
(incidence rate) was lower than the number of new 
diagnoses (notification rate) and was 3.6 per 100,000 
population (95% confidence interval (CI): 3.3–4.1) for 
the EU/EEA overall. This differed substantially between 
the four regions: the highest estimated incidence rate 
was in the West (5.2/100,000 population; 95% CI: 4.6–
5.9) and South (3.8; 95% CI: 2.8–4.8) and it was lower 
in the North (2.2; 95% CI: 2.0–3.4) and East (1.7; 95% 
CI 1.2–2.2).
Median time from infection to diagnosis
The median time from infection to diagnosis was esti-
mated to have declined in the EU/EEA overall and in 
all four regions between 2012 and 2016. In 2016, the 
EU/EEA median was 2.9 years (interquartile range: 1.4–
5.3) with some variation by region: South (3.6 years), 
East (3.0 years), West (2.6 years) and North (2.2 years) 
(Figure 2).
The estimated undiagnosed number of people living 
with HIV in 2016 was highest in the South and West 
(38,000 and 36,700, respectively), compared with 
17,500 in the North and 9,100 in the East (Figure 3). 
Over the period 2012–2016 the number of people esti-
mated to be living with undiagnosed HIV declined in 
the EU/EEA overall, from an estimated 132,200 in 2012 
to 101,400 in 2016. This decline was observed in all 
four regions, with a relatively more rapid decline in the 
South and particularly in recent years in the North. In 
2016, this resulted in lower estimated proportions of 
people living with undiagnosed HIV in the South, North 
and West (11.0%, 11.3%, and 12.1%, respectively) and a 
higher proportion in the East (16.8%).
Figure 1
Regions used in the analysis of undiagnosed HIV infections, European Union/European Economic Area, 2016
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EU/EEA: European Union/European Economic Area.
Countries’ grouping based on a United Nations definition [3].
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We estimated that 45% of those living with undiagnosed 
HIV in the EU/EEA in 2016 had a CD4 cell count of > 500 
cells/mm3, which suggests a relatively shorter duration 
of infection in this group (Figure 4). Conversely, 33% 
had an estimated CD4 cell count of < 350 cells/mm3, 
indicating a longer duration of HIV infection. Recency of 
infection varied by region, with the highest proportion 
of more recent infections observed in the West (51%) 
and the highest proportion of infections of longer dura-
tion in the South (37%). 
Discussion and conclusions
Our analysis provides evidence of a decline in the num-
ber of people living with undiagnosed HIV during the 
last 5 years in the EU/EEA. This decrease was more 
evident in the South and North regions. This may be 
associated with observed national-level declines in 
reported HIV notifications and newly acquired infec-
tions, evidence of more frequent testing and earlier 
diagnosis in some countries [7-10].
With a notification rate of 5.9 per 100,000 popula-
tion and an estimated incidence of 3.6 per 100,000, it 
appears that currently more individuals in the EU/EEA 
are being diagnosed than are newly infected with HIV. 
Between 2012 and 2016, the yearly diagnosed frac-
tion (yearly number of new diagnoses/(yearly number 
of new diagnoses + estimated number of undiagnosed 
people living with HIV)) increased from 20% to 23% 
[11]. This suggests that testing activities are ‘gaining 
ground’ on the hidden epidemic. If our estimates are 
accurate, if incidence does not increase unexpect-
edly, and if testing patterns remain stable or increase, 
this should result in further reductions in the number 
of undiagnosed people living with HIV and indicate 
progress towards achieving the global 2020 target 
of 90% of people living with HIV in the EU/EEA being 
diagnosed [12]. Currently there is heterogeneity across 
regions with regard to this target, with faster propor-
tional declines in the number of people living with 
undiagnosed HIV in the South and North regions. The 
highest proportions of people living with undiagnosed 
HIV are in the countries in the East region of the EU/
EEA.
Despite the welcome and positive trend in reduced 
numbers of undiagnosed infections, we estimated that 
it takes a median of 2.9 years from infection to diagno-
sis, and even more than 3 years in some regions of the 
EU/EEA. Shorter time to diagnosis is well-correlated 
with a higher CD4 cell count at diagnosis in the various 
regions; while the reverse is also true. It is well docu-
mented that early HIV diagnosis and rapid linkage to 
antiretroviral treatment for HIV results in lower HIV-
related morbidity and mortality for individuals infected 
[13], and in reduced HIV transmission at population-
level [14]. Diversifying and streamlining HIV testing 
programmes may improve access and uptake. Effective 
ways of doing this include augmenting routine testing 
Figure 2
Expected median time from HIV infection to diagnosis by 
year of infection, European Union/ European Economic 
Area and regionsa, 2012-2016
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Figure 3
Estimated number of undiagnosed HIV infections, EU/
EEA and regionsa, 2012–2016
CI: confidence interval; EU/EEA: European Union/ European 
Economic Area.
a Countries’ grouping based on a United Nations definition [3].
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for health conditions associated with HIV (‘indicator 
condition-guided testing’), increasing HIV testing dur-
ing screening for other sexually transmitted infections, 
and continuing to expand community-based testing, 
self-testing/home-sampling, and partner notification 
[15-17].
Our analysis is subject to several important limita-
tions. First, it is based on surveillance data and, while 
the quality of EU/EEA surveillance data are gener-
ally good and continue to improve year-on-year, some 
countries do not report CD4 cell count at diagnosis. Our 
assumption that the distribution of CD4 cell count was 
the same in these countries as for others in the same 
region could have resulted in less robust estimates 
by region. Second, the effect of migration on HIV inci-
dence and the undiagnosed number is complex and 
this was not accounted for in this analysis. Third, there 
is substantial variation in epidemic patterns within the 
four regions and overall results for a region cannot be 
directly applied to the individual countries within it 
with confidence. Often estimates for the region were 
heavily influenced by the countries with larger popu-
lation within the region. Still, our exercise points to 
the diversity of HIV incidence and in the undiagnosed 
population across Europe and underlines the need for 
increased availability of robust national estimates to 
guide and evaluate testing and prevention practice.
This analysis provides evidence that, although patterns 
across Europe are diverse, there appears to be a posi-
tive trend towards lower numbers of people living with 
undiagnosed HIV over time. Still, differences across 
the EU/EEA persist and these trends are not seen to 
the same extent in all the four regions analysed. We 
found that a substantial number of people are liv-
ing with undiagnosed HIV in the EU/EEA, that 33% of 
these have more advanced HIV infection, and that the 
median time from infection to diagnosis is still nearly 
3 years. Together this indicates that additional efforts 
are needed to increase the availability and uptake of 
HIV testing and rapid linkage to HIV treatment in coun-
tries in the EU/EEA.
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